ES2805085T3 - Epítopos de glipicano y usos de éstos - Google Patents

Epítopos de glipicano y usos de éstos Download PDF

Info

Publication number
ES2805085T3
ES2805085T3 ES15877381T ES15877381T ES2805085T3 ES 2805085 T3 ES2805085 T3 ES 2805085T3 ES 15877381 T ES15877381 T ES 15877381T ES 15877381 T ES15877381 T ES 15877381T ES 2805085 T3 ES2805085 T3 ES 2805085T3
Authority
ES
Spain
Prior art keywords
seq
epitope
substituted
amino acid
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15877381T
Other languages
English (en)
Spanish (es)
Inventor
Douglas Campbell
Fuenmayor Irene Justiniano
Aline Nocon
Julie Soon
Quach Truong
Bradley Walsh
Sandra Wissmueller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glyp Holdings Pty Ltd
Original Assignee
Glyp Holdings Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glyp Holdings Pty Ltd filed Critical Glyp Holdings Pty Ltd
Application granted granted Critical
Publication of ES2805085T3 publication Critical patent/ES2805085T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4722—Proteoglycans, e.g. aggreccan

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES15877381T 2015-01-16 2015-01-16 Epítopos de glipicano y usos de éstos Active ES2805085T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/AU2015/000019 WO2016112423A1 (en) 2015-01-16 2015-01-16 Glypican epitopes and uses thereof

Publications (1)

Publication Number Publication Date
ES2805085T3 true ES2805085T3 (es) 2021-02-10

Family

ID=56405046

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15877381T Active ES2805085T3 (es) 2015-01-16 2015-01-16 Epítopos de glipicano y usos de éstos

Country Status (11)

Country Link
US (3) US20180002391A1 (enExample)
EP (1) EP3245219B1 (enExample)
JP (1) JP6735005B2 (enExample)
KR (1) KR102435383B1 (enExample)
CN (1) CN107531755B (enExample)
AU (1) AU2015376851B2 (enExample)
CA (1) CA2973771A1 (enExample)
DK (1) DK3245219T3 (enExample)
ES (1) ES2805085T3 (enExample)
SG (1) SG11201705808XA (enExample)
WO (1) WO2016112423A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107108734B (zh) 2014-10-23 2021-09-14 美侬米克国际有限公司 单克隆抗gpc-1抗体和其用途
AU2016250900B2 (en) * 2015-04-20 2022-03-17 GlyTherix Ltd. Therapeutic antibodies and uses thereof
US20200308299A1 (en) * 2017-04-28 2020-10-01 National University Corporation Kochi University Anti-gpc-1 antibody
AU2020212534A1 (en) * 2019-01-22 2021-07-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High affinity monoclonal antibodies targeting glypican-1 and methods of use
CN111187350A (zh) * 2019-12-30 2020-05-22 西安英创生物技术有限公司 一种与磷脂酰肌醇蛋白聚糖-1结合的抗原结合蛋白
IT202200021546A1 (it) 2022-10-19 2024-04-19 Centro Di Riferimento Oncologico Di Aviano Anticorpo monoclonale anti-GPC1, suoi usi terapeutici e diagnostici
WO2025202359A1 (en) * 2024-03-27 2025-10-02 Adcendo Aps Anti-gpc1 antibodies and uses thereof
WO2025202361A1 (en) * 2024-03-27 2025-10-02 Adcendo Aps Anti-gpc1 antibodies and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356270A (en) 1977-11-08 1982-10-26 Genentech, Inc. Recombinant DNA cloning vehicle
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
WO1999037764A2 (en) * 1998-01-27 1999-07-29 Vlaams Interuniversitair Instituut Voor Biotechnologie New members of the glypican gene family
CA2346264A1 (en) * 1998-10-16 2000-04-27 Regents Of The University Of California Glypicans for the detection and treatment of human carcinoma
US20040226056A1 (en) * 1998-12-22 2004-11-11 Myriad Genetics, Incorporated Compositions and methods for treating neurological disorders and diseases
EP2208784B1 (en) * 2001-06-22 2013-01-02 Chugai Seiyaku Kabushiki Kaisha Cell proliferation inhibitors containing anti-glypican 3 antibody
DE602005024502D1 (de) * 2004-07-09 2010-12-16 Chugai Pharmaceutical Co Ltd Anti-glypican-3-antikörper
US20070087005A1 (en) * 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
US8270389B2 (en) 2008-08-11 2012-09-18 Marvell International Ltd. Method of synchronization for low power idle
CN102180969B (zh) * 2011-01-30 2013-04-10 中国人民解放军军事医学科学院微生物流行病研究所 抗肝癌活性单克隆抗体及其应用

Also Published As

Publication number Publication date
US20240247037A1 (en) 2024-07-25
EP3245219B1 (en) 2020-04-08
EP3245219A1 (en) 2017-11-22
EP3245219A4 (en) 2018-06-06
CA2973771A1 (en) 2016-07-21
KR20170109584A (ko) 2017-09-29
DK3245219T3 (da) 2020-06-29
AU2015376851A1 (en) 2017-07-27
SG11201705808XA (en) 2017-08-30
US20210107958A1 (en) 2021-04-15
JP6735005B2 (ja) 2020-08-05
JP2018504903A (ja) 2018-02-22
CN107531755B (zh) 2022-02-25
CN107531755A (zh) 2018-01-02
WO2016112423A1 (en) 2016-07-21
AU2015376851B2 (en) 2020-07-09
US20180002391A1 (en) 2018-01-04
KR102435383B1 (ko) 2022-08-24

Similar Documents

Publication Publication Date Title
ES2805085T3 (es) Epítopos de glipicano y usos de éstos
JP7479435B2 (ja) 癌治療および判断ターゲットとしてのｌｙ７５
ES2745014T3 (es) Proteína
ES2637151T3 (es) Tratamiento del linfoma de células T periféricas
CN107001453B (zh) 结合人p53线性表位的抗体及其诊断应用
Fayyad et al. Generation of monoclonal antibodies against phosphorylated α-Synuclein at serine 129: Research tools for synucleinopathies
KR20110000548A (ko) 신장암의 진단 또는 검출을 위한 조성물 및 방법
Jiang et al. Peptide mimic isolated by autoantibody reveals human arrest defective 1 overexpression is associated with poor prognosis for colon cancer patients
KR101976297B1 (ko) 혈장 면역 표지물-vegfr1 자가 항체를 검출하기 위한 항원 폴리펩티드 및 용도
JP2019108354A (ja) 治療的及び診断的標的としての不活性Ｎ−アセチル化−α−結合型酸性ジペプチダーゼ−様タンパク質２（ＮＡＡＬＡＤＬ２）
CN110221071A (zh) 预测女性对象患癌症风险或诊断其癌症的方法
KR20140083986A (ko) 항wt1 항체의 측정 방법
CN104861069B (zh) 针对间变性淋巴瘤激酶的单克隆抗体1a4及其用途
CN102834720A (zh) 谷蛋白引起的自身免疫性疾病的诊断
JP7053058B2 (ja) グリピカンエピトープおよびその使用
ES2797089T3 (es) Anticuerpo IGF-1R y su utilización para el diagnóstico del cáncer
KR20120028603A (ko) 돼지인플루엔자 바이러스 헤마글루티닌 검출용 항체 및 이의 용도
Hodek et al. Preparation and application of anti-peptide antibodies for detection of orphan cytochromes P450
JP6861349B2 (ja) Ｃｄ８１ ｌｅｌ特異的モノクローナル抗体
KR101776922B1 (ko) 저선량 방사선 노출에 대한 특이 반응 지표로서 다클론 Ikaros (serine 391/393) 인산화 항체 개발 및 이의 용도
HK1238267B (en) Glypican epitopes and uses thereof
CA3228822A1 (en) Glycoprotein biomarkers for diagnosing cancer
RU2023100156A (ru) Диагностические анализы и наборы для детекции фолатного рецептора 1
RU2018133493A (ru) Диагностические анализы и наборы для детекции фолатного рецептора 1